Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirfenidone + sintilimab
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pirfenidone + sintilimab is an experimental combination therapy being investigated for the treatment of colorectal cancer with peritoneal metastasis. This regimen combines pirfenidone, an antifibrotic small molecule typically used for idiopathic pulmonary fibrosis, with sintilimab, a recombinant humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. In the context of peritoneal metastasis, pirfenidone is hypothesized to modulate the dense fibrotic tumor microenvironment (desmoplasia), potentially enhancing the penetration and efficacy of immunotherapy and concurrent chemotherapy. Sintilimab acts as a checkpoint inhibitor, restoring T-cell antitumor activity. This combination is being studied in clinical trials led by Guoxiang Cai, often in conjunction with standard neoadjuvant chemotherapy (CapeOX).
- Other names
- pirfenidone plus sintilimab
02
Targets
MMP9 (Matrix metalloproteinase-9)MUC1-C/SMAD3/beta-catenin (Mucin 1 C-terminal subunit/SMAD3/beta-catenin complex)PDCD1 (Programmed cell death protein 1 receptor)NFKB1 (NF-κB1)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on pirfenidone + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirfenidone + sintilimab.